Evolutionary Genomics

Evolutionary Genomics Market capitalization

The The market capitalization of Evolutionary Genomics (FNAM) as of Nov 19, 2026 is 1,331.05 USD. In the previous year, The market capitalization was 1,331.05 USD — a change of 0.00% (lower).

Market capitalization

1,331.05USD

YoY

0.00%

Last updated:

In 2022, Evolutionary Genomics's market cap stood at 1,331.05 USD, a 0.00% increase from the 1,331.05 USD market cap in the previous year.

The Evolutionary Genomics Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2015
1,331.05 USD
Jan 1, 2016
1,331.05 USD
Jan 1, 2017
1,331.05 USD
Jan 1, 2018
1,331.05 USD
Jan 1, 2019
1,331.05 USD
Jan 1, 2020
1,331.05 USD
Jan 1, 2021
1,331.05 USD
Jan 1, 2022
1,331.05 USD
The Evolutionary Genomics Market capitalization history
YEARMarket capitalizationYoY
1,331.05USD0.00%
1,331.05USD0.00%
1,331.05USD0.00%
1,331.05USD0.00%
1,331.05USD0.00%
1,331.05USD0.00%
1,331.05USD0.00%
1,331.05USD0.00%
1,331.05USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Evolutionary Genomics Stock analysis

What does Evolutionary Genomics do? Evolutionary Genomics, Inc. generates revenue through the identification and validation of genes impacting commercially valuable traits in crops for the agriculture industry. The company utilizes its Adapted Traits Platform (ATP) to identify genes that control important traits in plants and animals, focusing on yield increases in corn and rice, drought tolerance, sugar content in tomatoes, and pest/disease resistance in soybeans, cassava, beans, tomatoes, and cotton. The firm applies ATP in research projects for agricultural clients seeking improved crop performance. The company targets agricultural industry clients who require gene-based solutions for enhancing crop traits such as yield, drought tolerance, and pest resistance. The Adapted Traits Platform (ATP) is central to the company's product offering, enabling throughput molecular evolution analysis through non-synonymous site (Ka) and synonymous site (Ks) analysis to identify positively selected genes. This platform identifies genes that have successfully adapted to impart new or improved traits in agricultural crops. The firm's research projects include specific applications like yield increases in corn and rice, drought tolerance in crops, and pest resistance in soybeans, cassava, beans, tomatoes, and cotton. Agricultural companies and research institutions are the primary buyers of these gene identification services. Evolutionary Genomics, Inc. focuses on the agriculture industry, specifically targeting clients who need gene validation for crop improvement. The company's services are used to identify genes responsible for commercially valuable traits such as yield, drought tolerance, and pest resistance. The firm's ATP platform is applied in research projects for crops including corn, rice, soybeans, cassava, beans, tomatoes, and cotton. Agricultural clients seeking to enhance their crop traits through gene-based solutions are the key market segment for the company's offerings. Evolutionary Genomics is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Evolutionary Genomics's Market Capitalization

Evolutionary Genomics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Evolutionary Genomics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Evolutionary Genomics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Evolutionary Genomics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Evolutionary Genomics stock

The market capitalization of Evolutionary Genomics is 1,331.05 USD in 2022.

The market capitalization of Evolutionary Genomics changed from 1,331.05 USD to 1,331.05 USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Evolutionary Genomics since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Evolutionary Genomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Evolutionary Genomics

All Key Metrics — Evolutionary Genomics